Navigation Links
The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
Date:9/21/2010

BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Type 2 Diabetes reveal that agents from the incretin mimetics drug class—dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) analogues—are the most promising drug classes because they improve upon key areas of safety and efficacy. DPP-IV inhibitors such as Januvia have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues such as Bydureon and Byetta combine superior glucose-lowering and weight-loss capabilities and are particularly useful for the significant proportion of type 2 diabetics who are obese. Among all drug classes, DPP-IV inhibitors and GLP-1 analogues will experience the largest upturn in market share, increasing from 12 percent in 2009 to 30 percent in 2019.

"Januvia dominates the DPP-IV inhibitor class and will consolidate its leading position while other DPP-IV inhibitors will struggle, owing to their lack of clinical advantages over Januvia," said Decision Resources Analyst Yannick Maneuf, Ph.D. "GLP-1 analogues have a strong efficacy profile, they elicit weight loss and also have limited safety liabilities and—despite requiring an injection—GLP-1 analogues enjoy great popularity among thought leaders, who see improved glycemia and weight loss in obese type 2 diabetics as landmark progress."

Bydureon, a once-weekly therapy, will earn the most sales in the GLP-1 analogue class, based on its convenience and efficacy. Bydureon and Novo Nordisk's once-daily Victoza will also benefit as a result of the failure of Roche/Ipsen/Teijin/Chugai's taspoglutide, which was the second-most-advanced contender among the long-acting GLP-1 analogues.

The Pharmacor 2010 findings also reveal that although an advisory committee of the U.S. Food and Drug Administration recently agreed to keep GlaxoSmithKline's PPAR-gamma agonist Avandia on the market, the drug will continue to lose sales through 2019 to its main competitor from the same drug class, Takeda's Actos.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
2. Interventional Spine®, Inc. Announces Continued Success With Its Unique PERPOS® Percutaneous Cervical System
3. K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards
4. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
5. Department of Defense Funding Shows Continued and Bi-Partisan Support for STB® Lifesaving Technologies Products to Stop Blood Loss
6. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
7. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
8. Philips Introduces Breakthrough Medical Alert Service That Helps Enable Continued Independence for Seniors by Improving Access to Help in the Event of a Fall
9. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
10. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
11. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):